Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis

NCT03474198 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

675

Enrollment

OTHER

Sponsor class

Conditions

Tuberculosis, Pulmonary

Interventions

DRUG: Rifampicin
DRUG: Isoniazid
DRUG: Pyrazinamide
DRUG: Ethambutol
DRUG: Linezolid
DRUG: Clofazimine
DRUG: Rifapentine
DRUG: Levofloxacin
DRUG: Bedaquiline
DRUG: Rifampicin

Sponsor

University College, London

Collaborators

[object Object]
[object Object]